Cellectis
Research Cellectis (CLLS) on Bullrun: market cap USD 295.80M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCLLS
- ExchangeNASDAQ
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 295.80M
- Financial periodQ1 2026
- RevenueUSD 5.78M
- Net income-USD 17.77M
- Free cash flow-USD 41.05M
- Gross margin59.8%
Valuation Snapshot
latest market cap is USD 295.80M.
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL;
Frequently asked questions
What is Cellectis's market cap?
Cellectis's market capitalization is USD 295.80M.
What does Cellectis do?
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.